The last time The Lancet Microbe featured an Editorial on CRISPR was in November 2020, to mark that year’s Nobel Prize in Chemistry, jointly awarded to Emmanuelle Charpentier and Jennifer A Doudna for ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Bill Whitaker is an award-winning journalist and 60 Minutes correspondent who has covered major news stories, domestically and across the globe, for more than four decades with CBS News. America's ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $55.72, moving -1.83% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.26%. On ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...